Contact investigations as a means of detection and timely treatment of persons with infectious multidrug-resistant tuberculosis

International Journal of Tuberculosis and Lung Disease

Volumn 7, Issue 12 SUPPL. 3, 2003, Pages

  Bayona, J ^a,b   Chavez Pachas, A M ^c   Palacios, E ^a   Llaro, K ^a   Sapag, R ^a   Becerra, Mercedes C ^b  

^a Socios Salud Suc Peru/Ptnrs Hlth   (Peru)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Laboratorio Regional   (Peru)

Author keywords

Case finding; Contact investigations; DOTS Plus; Multidrug resistant tuberculosis; Peru

Indexed keywords

CAPREOMYCIN; CIPROFLOXACIN; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; ANTIBIOTIC SENSITIVITY; CASE FINDING; CHILD; CLINICAL PROTOCOL; CONVALESCENCE; DRUG EFFICACY; ENDEMIC DISEASE; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; PERU; PRIORITY JOURNAL; PROFESSIONAL PRACTICE; RETROSPECTIVE STUDY; REVIEW; SHORT COURSE THERAPY; TUBERCULOSIS; TUBERCULOSIS CONTROL;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; CONTACT TRACING; FEMALE; HUMANS; INFANT; MALE; MIDDLE AGED; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PERU; RETROSPECTIVE STUDIES; TIME FACTORS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 0347533712     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Etkind S C, Veen J. Contact follow-up in high- and low-prevalence countries. In: Reichman L B, Hershfield E S, eds. Tuberculosis - A Comprehensive International Approach. 2d ed. New York: Marcel Dekker, Inc., 2000: 377-399.
2. Mohle-Boetani J C, Flood J. Contact investigations and the continued commitment to control tuberculosis. JAMA 2002; 287: 1040-1042.
3. Behr M A, Hopewell P C, Paz E A, Kawamura L M, Schecter G F, Small P M. Predictive value of contact investigation for identifying recent transmission of Mycobacterium tuberculosis. Am J Respir Crit Care Med 1998; 158: 465-469.
4. Noertjojo K, Tam C M, Chan S L, Tan J, Chan-Yeung M. Contact examination for tuberculosis in Hong Kong is useful. Int J Tuberc Lung Dis 2002; 6: 19-24.
5. Topley J M, Maher D, Mbewe L N. Transmission of tuberculosis to contacts of sputum positive adults in Malawi. Arch Dis Child 1996; 74: 140-143.
6. Kuaban C, Koulla-Shiro S, Lekama Assiene T, Hagbe P. Tuberculosis screening of patient contacts in 1993 and 1994 in Yaounde, Cameroon. Med Trop 1996; 56: 156-158.
7. Marks S M, Taylor Z, Qualls N L, Shrestha-Kuwahara R J, Wilce M A, Nguyen C H. Outcomes of contact investigations of infectious tuberculosis patients. Am J Respir Crit Care Med 2000; 162: 2033-2038.
8. Ministerio de Salud. Actualización de la doctrina, normas y procedimientos para el control de la tuberculosis en el Perú. Peru: Dirección General de Salud de las Personas, Ministerio de Salud, 2001.
9. Snider D E Jr, Kelly G D, Cauthen G M, Thompson N J, Kilburn J O. Infection and disease among contacts of tuberculosis cases with drug-resistant and drug-susceptible bacilli. Am Rev Respir Dis 1985; 132: 125-132.
10. Becerra M C, Freeman J, Bayona J, et al. Using treatment failure under effective directly observed short-course chemotherapy programs to identify patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2000; 4: 108-114.
11. Farmer P E, Kim J Y, Mimick C D, Timperi R. Responding to outbreaks of MDRTB: introducing DOTS-Plus. In: Reichman L B, Hershfield E S, ed. Tuberculosis-A Comprehensive International Approach. Second ed. New York: Marcel Dekker, Inc., 2000: 447-469.
12. Farmer P E, Furin J J, Shin S S. Managing multidrug-resistant tuberculosis. J Respir Dis 2000; 21: 53-56.
13. Mitnick C, Bayona J, Palacios E, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med 2003; 348: 119-128.
14. Centers for Disease Control and Prevention. Self-Study Modules on Tuberculosis: Contact Investigations for Tuberculosis. Atlanta, GA: CDC, 1999.
15. Reichler M R, Reyes R, Bur S, et al. Evaluation of investigations conducted to detect and prevent transmission of tuberculosis. JAMA 2002; 287: 991-995.
16. Vasquez L, Asencios L, Quispe N, et al. Vigilancia de la resistencia a los medicamentos antituberculosos en el Perú, 1995-1996. Rev Med Exp INS-PERU 1997; 14: 5-14.
17. WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance. Anti-Tuberculosis Drug Resistance in the World, 2000. WHO/CDS/TB/2000.278, Geneva: WHO, 2000.
18. Devadatta S, Dawson J J Y, Fox W, et al. Attack rate of tuberculosis in a 5-year period among close family contacts of tuberculosis patients under domiciliary treatment with isoniazid plus PAS or isoniazid alone. Bull World Health Organ 1970; 42: 337-351.
19. Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR 2000; 49:(RR 06): 1-51.
20. Centers for Disease Control and Prevention. Update: fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations - United States, 2001. MMWR 2001; 50: 733-735.
21. Mehta J, Diaz C, Guha B, Harvill L, Krishnaswamy G. Appearance of drug-resistant tuberculosis in rural Tennessee. South Med J 1995; 88: 60-64.
22. Teixeira L, Perkins M D, Johnson J L, et al. Infection and disease among household contacts of patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2001; 5: 321-328.
23. Becerra M C. Epidemiology of tuberculosis in the northern shantytowns of Lima, Peru. Sc.D. thesis. Boston, MA: Harvard University, 1999.
24. Styblo K. Epidemiology of tuberculosis. In: Selected Papers, Royal Netherlands Tuberculosis Association, Vol. 24, 1991. The Hague: Broekmans, 1991.
25. Ferebee S H. Controlled chemoprophylaxis trials in tuberculosis: a general review. Adv Tuberc Res 1970; 17: 28-106.
26. British Thoracic Association. A study of standardised contact procedure in tuberculosis. Tubercle 1978; 59: 245-259.
27. Selby C D, Allen M B, Leitch A G. Optimal duration of follow-up for tuberculosis contacts. Respir Med 1989; 83: 353-355.
28. Teale C, Cundall D B, Pearson S B. Time of development of tuberculosis in contacts. Respir Med 1991; 85: 475-477.
29. Kritski A L, Marques M J, Rabahi M F, et al. Transmission of tuberculosis to close contacts of patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med 1996; 153: 331-335.
30. Steiner P, Rao M, Mitchell M, Steiner M. Primary drug-resistant tuberculosis in children. Correlation of drug-susceptibility patterns of matched patient and source case strains of Mycobacterium tuberculosis. Am J Dis Child 1985; 139: 780-782.
31. Starke J R, Taylor-Watts K T. Tuberculosis in the pediatric population of Houston, Texas. Pediatrics 1989; 84: 28-35.
32. Centers for Disease Control. Multi-drug resistant tuberculosis-North Carolina. MMWR 1987; 35(51-52): 785-787.
33. Schaaf H S, Van Rie A, Gie R P, et al. Transmission of multi-drug-resistant tuberculosis. Pediatr Infect Dis J 2000; 19: 695-659.
34. Furin J J, Becerra M C, Shin S S, Kim J Y, Bayona J, Farmer P E. Effect of administering short-course, standardized regimens in individuals infected with drug-resistant Mycobacterium tuberculosis strains. Eur J Clin Microbiol Infect Dis 2000; 19: 132-136.
35. Farmer P E, Bayona J, Becerra M C, et al. The dilemma of MDR-TB in the global era. Int J Tuberc Lung Dis 1998; 2: 869-876.
36. Centers for Disease Control. Initial therapy for tuberculosis in the era of multidrug-resistance: recommendations of the Advisory Council for the Elimination of Tuberculosis. MMWR 1993; 42(RR-7): 1-8.
37. Frieden T R, Sherman L F, Maw K L, et al. A multi-institutional outbreak of highly drug-resistant tuberculosis: epidemiology and clinical outcomes. JAMA 1996; 276: 1229-1235.
38. Telzak E E, Sepkowitz K, Alpert P, et al. Multidrug-resistant tuberculosis in patients without HIV infection. N Engl J Med 1995; 333: 907-911.
39. Saravia J C, Sarria M, Jave H O. Treatment outcomes of the first-line regimen among contacts of multidrug-resistant tuberculosis patients. Int J Tuberc Lung Dis 2001; 5 (Suppl 1): S242.
40. Webb R, Fernandez-Baca G. [Peru in numbers 1997: annual statistics]. [Spanish]. Lima, Perú: Cuanto SA, 1997.
41. UNAIDS. Epidemiological fact sheets on HIV/AIDS and sexually transmitted infections-Peru. 2002 Update. Available at: http://www.who.int/emc-hiv/fact_sheets/pdfs/peru_en.pdf
42. Escalante P, Ramaswamy S, Sanabria H, et al. Genotypic characterization of drug-resistant Mycobacterium tuberculosis isolates from Peru. Tubercle Lung Dis 1998; 79: 111-118.